SCIENTIFIC PROGRAMME
SESSION I
HOW I TREAT
SMOLDERING MYELOMA
(SMM)
SESSION II
HOW I TREAT NEWLY
DIAGNOSED MULTIPLE
MYELOMA
SESSION III
FROM RISK
STRATIFICATION TO
RISK-BASED THERAPY?
DEBATE 1
SHOULD WE USE MRD
TESTING TO DETERMINE
THERAPY IN MULTIPLE
MYELOMA?
DEBATE 2
IS THERE A FUTURE ROLE
OF AUTOLOGOUS STEM
CELL TRANSPLANTATION?
SESSION IV
HOW I TREAT RELAPSED
MULTIPLE MYELOMA
DEBATE 3
SHOULD EVERY PATIENT
RECEIVE DARATUMUMAB
IN FIRST LINE?
ROUNDTABLE
MULTIPLE MYELOMA
FROM THE PERSPECTIVE
OF FDA/EMEA AND
FOUNDATIONS
SESSION V
YOU CAN’T BE IMMUNE
FOR IMMUNE THERAPY
ANYMORE
SESSION VI
OTHER PLASMA CELL
DYSCRASIAS
KEYNOTE LECTURES
THE FUTURE OF
MULTIPLE MYELOMA
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
ABSTRACTS SELECTED
AS POSTERS
DISCLOSURES
SELECTED ABSTRACTS FOR POSTER PRESENTATIONS
IN ALPHABETIC ORDER ACCORDING TO THE NAME OF THE FIRST AUTHOR
BIOLOGY POSTERS
Poster 1: IMPROVING THE RISK STRATIFICATION OF MULTIPLE MYELOMA WITH A
DNA/RNA EDITORS-BASED SCORING SYSTEM
Sarah Grasediec, Afsaneh M. Shariatpanahi, Matthew C. Jarvis, Faezeh Borzooee,
Reuben S. Harris, Mani Larijani, Kevin Song, Arefeh Rouh and Florian Kuchenbaue
Poster 2: ONCOLYTIC IFNΒ/ΗF LENTIVIRAL VECTOR REDUCES MYELOMA CELL SURVIVAL
BY INDUCING APOPTOSIS
Eleni Kalafati, Ekati Drakopoulou, Tina Bagratuni, Evangelos Terpos, Evgenia Tsempera,
Maria K. Angelopoulou, Els Verhoeyen, Francois Louic Cosset, Konstantinos
Konstantopoulos, Eleni Papanikolaou and Nicholas P. Anagnou
Poster 3: A DELETION IN THE NFKB1 GENE PROMOTER AS A POTENTIAL MARKER OF
SURVIVAL IN MALE PATIENTS WITH MULTIPLE MYELOMA
Piotr Lacina, Aleksandra Butrym, Barbara Wysoczanska, Grzegorz Mazur and Katarzyna
Bogunia-Kubik
Poster 4: FLOWER-LIKE PLASMA CELL NUCLEI IN MULTIPLE MYELOMA
Abibatou Sall, Moussa Seck, Seynabou Fall, Blaise Félix Faye, Macoura Gadji, Fatou
Samba Ndiaye, Saliou Diop and Awa Oumar Touré